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Abstract
Background: Although the minimization of the applied tidal volume (VT) during high-frequency
oscillatory ventilation (HFOV) reduces the risk of alveolar shear stress, it can also result in
insufficient CO2-elimination with severe respiratory acidosis. We hypothesized that in a model of
acute respiratory distress (ARDS) the application of high oscillatory frequencies requires the
combination of HFOV with arteriovenous extracorporeal lung assist (av-ECLA) in order to
maintain or reestablish normocapnia.
Methods: After induction of ARDS in eight female pigs (56.5 ± 4.4 kg), a recruitment manoeuvre
was performed and intratracheal mean airway pressure (mPaw) was adjusted 3 cmH2O above the
lower inflection point (Plow) of the pressure-volume curve. All animals were ventilated with
oscillatory frequencies ranging from 3–15 Hz. The pressure amplitude was fixed at 60 cmH2O. At
each frequency gas exchange and hemodynamic measurements were obtained with a clamped and
de-clamped av-ECLA. Whenever the av-ECLA was de-clamped, the oxygen sweep gas flow through
the membrane lung was adjusted aiming at normocapnia.
Results: Lung recruitment and adjustment of the mPaw above Plow resulted in a significant
improvement of oxygenation (p < 0.05). Compared to lung injury, oxygenation remained
significantly improved with rising frequencies (p < 0.05). Normocapnia during HFOV was only
maintained with the addition of av-ECLA during frequencies of 9 Hz and above.
Conclusion:  In this animal model of ARDS, maximization of oscillatory frequencies with
subsequent minimization of VT leads to hypercapnia that can only be reversed by adding av-ECLA.
When combined with a recruitment strategy, these high frequencies do not impair oxygenation
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Background
The current strategy for conventional mechanical ventila-
tion (CMV) in patients with acute respiratory distress syn-
drome (ARDS) is to prevent further lung injury which is a
result of alveolar over-distension and the repetitive col-
lapse and reopening of damaged alveoli [1-3]. Lung-pro-
tective ventilation using low tidal volume (VT) has been
shown to reduce ventilator-induced lung injury (VILI) and
mortality in patients with ARDS [2,4,5]. Theoretically
high-frequency oscillatory ventilation (HFOV) achieves
all goals of a lung-protective ventilatory mode. It provides
the application of extremely small VTs combined with a
relatively high mean airway pressure (mPaw). Thereby a
more uniform lung recruitment can be achieved while the
risk of tidal overdistension is minimized [6,7]. In adults
with ARDS, HFOV can be safely applied and may improve
gas exchange compared with CMV [8]. During HFOV, VT
and thus carbon dioxide (CO2)-elimination are directly
related to the applied pressure amplitude (ΔP) and the
inspiratory/expiratory ratio and are inversely related to
the oscillatory frequency- in other words: The lower the
oscillatory frequency, the higher the resulting VT [9].
In adult HFOV trials the applied frequencies varied from
3–6 Hz and, in an attempt to maximize CO2-elimination,
a ΔP from 60–90 cmH2O was used [10,11]. In these set-
tings the resulting VTs resemble those during conven-
tional lung-protective ventilation, thereby antagonizing
the potential advantages of HFOV [9,12]. Although it was
shown that higher oscillatory frequencies (15 Hz) might
result in less neutrophil infiltration compared with lower
frequencies (5 Hz) in a small animal model of respiratory
distress, in adults the application of higher frequencies
may lead to insufficient CO2-elimination with severe res-
piratory acidosis [13-15].
Recently, a new pumpless arteriovenous extracorporeal
lung assist system (av-ECLA) has been introduced into
clinical practice. It consists of a low-resistance membrane
lung (iLA, NovaLung®, Hechingen, Germany) interposed
into a simple arteriovenous shunt between the femoral
artery and vein [16]. Depending on the diameter of the
cannulas, the cardiac output (CO) and the mean arterial
pressure (MAP), the transmembraneous blood flow
equals 20–30% of the CO [17]. With these flow rates near
total extracorporeal CO2-removal could be achieved in
animal models of respiratory failure, thereby allowing a
more lung protective conventional ventilation strategy
[18,19].
While significant reductions in minute ventilation and
VTs can be obtained during the combination of av-ECLA
and conventional mechanical ventilation, optimal oscilla-
tory frequencies remain to be determined. The current
study was performed to evaluate the effects of different
oscillatory frequencies on CO2-elimination with and
without av-ECLA in a large-animal model of ARDS. We
hypothesized that the application of high oscillatory fre-
quencies, and thereby minimization of VT and alveolar
stretch, requires the combination of HFOV with av-ECLA
in order to maintain or re-establish normocapnia.
Methods
Animal Preparation
The study was conducted in accordance with the National
Institutes of Health guidelines for ethical animal research
and was approved by the Laboratory Animal Care and Use
Committee of the District of Unterfranken, Germany. The
experiments were performed on eight healthy female pigs
(56.5 ± 4.4 kg). Anaesthesia and instrumentation were
carried out as previously described [20].
Shortly after intramuscular premedication with ketamin
(10 mg/kg,) an intravenous line was obtained and the ani-
mals were anaesthesized with continuous infusion of 5–
10 mg/kg thiopental and 0.01 mg/kg/h fentanyl through-
out the experiment. Neuromuscular block was achieved
by continuous infusion of 0.1 mg/kg/h pancuronium.
The trachea was intubated with a cuffed 8.5 mm ID
endotracheal tube with an additional side lumen ending
at the tip (Rueschelit®, Ruesch, Kernen, Germany). The
lung was mechanically ventilated in the pressure control-
led ventilation mode (EvitaXL, Dräger Medical, Lübeck,
Germany) starting with a PEEP of 5 cmH2O, a VT of 6 ml/
kg, a respiratory rate (RR) of 30/min and an inspiratory to
expiratory ratio (I:E) of 1:1. The inspiratory oxygen frac-
tion (FiO2) remained 1.0 throughout the entire experi-
ment. The core temperature was maintained at 38.0 ±
0.5°C during the experiment by using a heating pad.
The animals were instrumented with a central venous line
(Arrow International, Reading, PA, USA), an arterial cath-
eter (Vygon, Ecouen, France) and a pulmonary artery cath-
eter (831F75, Edwards Lifescience, Irvine, CA, USA). The
position of the pulmonary artery catheter was verified by
typical waveforms. After systemic heparinization (400 U/
kg, Liquemin, Roche, Reinach, Switzerland) a 17 -French
cannula was inserted into the right femoral artery and a
17-French cannula (NovaLung®, Hechingen, Germany)
into the left femoral vein using Seldinger technique and
ultrasound guidance (SonoSite 180 Plus, SonoSite Inc.,
Botell, WA). A low-resistance pumpless extracorporeal
lung assist device (iLA, NovaLung®, Hechingen, Germany)
was primed with heparinized isotonic saline (150 ml) and
connected to the femoral cannulas. The av-ECLA circuit
was afterwards occluded with tubing clamps. The acti-
vated clotting time (ACT II, Medtronic, Minneapolis, MN)
was measured hourly and maintained between 300–400BMC Anesthesiology 2008, 8:7 http://www.biomedcentral.com/1471-2253/8/7
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seconds with continuous heparin infusion (1000 – 2000
U/h).
Experimental Protocol
The study protocol of the experiment is outlined in Fig. 1.
After instrumentation, the animals were stabilized for 30
min and baseline measurements (TBaseline)were obtained.
Severe ARDS (TARDS) was induced by bilateral pulmonary
lavages with 30 ml/kg isotonic saline (38°C), repeated
every 10 minutes until PaO2 decreased to less than 60
mmHg and remained stable for 60 minutes with
unchanged ventilator settings. An average of 7 ± 2 lavages
with approximately 12.000 ml saline per animal was nec-
essary for ARDS induction. During induction all animals
were ventilated with PCV (FiO2 = 1.0, PEEP = 5 cmH2O,
VT = 6 ml/kg, RR = 30/min, I:E = 1:1). After the induction
of ARDS the lower inflection point (Plow) of the thoracic
pressure-volume curve (PV) was determined in each ani-
mal. Accordingly, the animals were switched from PCV to
HFOV (Sensor Medics 3100 B, Yorba Linda, CA, USA) and
a lung recruitment manoeuvre (RM) was performed. This
was realized by increasing the mean airway pressure
(mPaw) to 50 cmH2O without oscillations for 40 s. The
intratracheal mPaw was then adjusted 3 cmH2O above
Plow. Afterwards, HFOV was started with an oscillatory
frequency of 3 Hz and RM measurements were obtained
(TRM). Subsequently, the animals were ventilated with
oscillatory frequencies ranging from 3 Hz to 15 Hz. The
frequency was altered in steps of 3 Hz in an incremental
or decremental order. The starting oscillatory frequency
was randomly assigned (3 Hz or 15 Hz to each half of the
animals) to rule out a time effect in gas exchange and
hemodynamic measurements due to recovery of the
injured lung. At each oscillatory frequency, measurements
were obtained with the av-ECLA circuit opened and
closed. A 30-minute period was given for equilibration
between each modification prior to data collection. The
total study period lasted approximately 6 hours. As the av-
ECLA circuit was de-clamped, normocapnia was
attempted by adjusting the sweep gas flow through the
membrane lung (0 – 10 l oxygen/min), which was applied
via a calibrated O2-flowmeter (Draeger, Luebeck, Ger-
many). Ventilator settings during HFOV were set as fol-
lows throughout the trial: FiO2 = 1.0, bias flow = 30 l/min,
oscillatory pressure amplitude = 60 cmH2O, I:E = 1:1. At
the end of the study the oscillatory frequency was set at 3
Hz with the av-ECLA circuit clamped. A continuous col-
loid infusion (Voluven® 6% HES 130/0.4, Fresenius Kabi,
Bad Homburg, Germany) was administered in addition to
a balanced electrolyte solution to maintain a mean arte-
rial pressure (MAP) > 70 mmHg, which is mandatory to
maintain sufficient blood flow through the membrane
lung. Before killing the animals with an overdose of thio-
pental and embutramid mebezonium iodide (T 61®,
Intervet, Unterschleissheim, Germany) the PV curve was
repeatedly measured.
Measurements
All measurements were performed during HFOV at differ-
ent oscillatory frequencies (3, 6, 9, 12 or 15 Hz) with the
av-ECLA circuit opened or closed (Fig. 1). For hemody-
namic monitoring pressure transducers referenced to
atmospheric pressure at the mid-thoracic level (Combi-
trans®, Braun, Melsungen, Germany) and a modular mon-
itor system (Servomed®, Hellige, Freiburg i. Br., Germany)
were used. MAP, mean pulmonary artery pressure
(MPAP), central venous pressure (CVP) and pulmonary
artery occlusion pressure (PCWP) were transduced. The
heart rate (HR) was traced by the electrocardiogram.
Threefold injections of 10-ml aliquots of ice cold saline
into the right atrium were used for pulmonary artery cath-
eter-based cardiac output measurements (Explorer®,
Edwards Lifescience, Irvine, CA, USA).
Blood flow through the extracorporeal circuit was meas-
ured continuously with an ultrasonic flow probe (HT
110®, Transonic, Ithaca, NY, USA). Arterial, post av-ECLA
and mixed venous blood samples were immediately ana-
lyzed for PO2, PCO2 and pH using standard blood gas
electrodes (ABL 505®, Radiometer, Bronshoj, Denmark).
In each sample, hemoglobin and oxygen saturation were
measured using spectrophotometry (OSM3®, Radiometer,
Bronshoj, Denmark). Arterial and mixed venous oxygen
contents (ml/dl) and the pulmonary shunt fraction (Qs/
Qt) were calculated using standard formulas.
Intratracheal mean airway pressure (mPaw) was meas-
ured at the tubes tip using an air filled pressure transducer
referenced to atmospheric pressure (PM8050®, Draeger,
Luebeck, Germany). Quasistatic pressure-volume curves
of the respiratory system were obtained using the in- and
expiratory low-flow pressure-volume manoeuvre of the
Evita XL® ventilator. The start pressure was set at 0 cmH2O
and the peak inspiratory pressure at 50 cmH2O with a
flow rate of 4 l/min and a maximum volume of 2 l.
Statistical analysis
In each animal, both the starting oscillatory frequency (3
Hz or 15 Hz in each half of the animals; variation of fre-
quency in steps of 3 Hz every 30 min) and the order of
opening and closing the av-ECLA at each frequency were
randomized. The data of the incremental and decremental
oscillatory trial were pooled and analyzed using SigmaStat
2.03 (Systat Software Inc., Point Richmond, USA). The
data were tested for normal distribution using the Kol-
mogorov-Smirnov test. Values are reported as mean ± SD.
One and two-way analysis of variance (ANOVA) for
repeated measurements were used for data analysis. Stu-
dent-Newman-Keuls post hoc test was used for compari-BMC Anesthesiology 2008, 8:7 http://www.biomedcentral.com/1471-2253/8/7
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Study protocol and time course Figure 1
Study protocol and time course. PCV, Pressure controlled ventilation; HFOV, high-frequency oscillatory ventilation; FiO2, 
fraction of inspired oxygen; PEEP, positive endexpiratory pressure; VT, tidal volume; RR, respiratory rate; I:E, inspiratory:expir-
atory-ratio; mPaw, mean pulmonary airway pressure; Plow, lower inflection point of the pressure-volume curve; PaO2, arterial 
oxygen partial pressure; PaCO2, carbon dioxide partial pressure; av-ECLA, arteriovenous extracorporeal lung assist device.BMC Anesthesiology 2008, 8:7 http://www.biomedcentral.com/1471-2253/8/7
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son of significant ANOVA results. Adjustment for
multiple testing was performed. P values < 0.05 were con-
sidered significant.
Results
All animals survived the complete study period. Gas
exchange and hemodynamic parameters did not differ
between the animals randomized for the incremental or
decremental oscillatory trial before and after lung injury.
After saline lavage, all animals developed severe respira-
tory failure (Table 1, Fig. 2, 3, and 4). Detailed data
regarding gas exchange, respiratory parameters, hemody-
namics and av-ECLA related parameters, are presented in
Tables 1 and 2.
Pulmonary Gas Exchange
Lung recruitment and adjusting the mPaw 3 cmH2O
above Plow during HFOV led to a significant improve-
ment of PaO2, SvO2, and Qs/Qt-ratio (Table 1, Fig. 3, and
4, p < 0.05). At TRM, at 3 Hz/ECLA and at 3 Hz, PaCO2 was
significantly reduced and pH was significantly increased
compared with TARDS (Table 1, p < 0.05). PaO2 and Qs/Qt-
ratio remained significantly improved with rising oscilla-
tory frequencies compared with TARDS (Table 1 and Fig. 4,
p < 0.05). Pulmonary shunt fraction was significantly
higher between 6 Hz and 12 Hz during HFOV compared
with HFOV/av-ECLA (Table 1, p < 0.05). PaCO2 was sig-
nificantly reduced and pH was significantly higher
between 6 Hz and 15 Hz with the av-ECLA opened as
compared with HFOV alone (Table 1 and Fig. 2, p < 0.05).
SvO2  was significantly higher during HFOV/av-ECLA
compared with HFOV with all oscillatory frequencies
Arterial carbon dioxide partial pressure (PaCO2) during different oscillatory frequencies with the arteriovenous extracorpor- eal lung assist device (ECLA) opened and closed Figure 2
Arterial carbon dioxide partial pressure (PaCO2) during different oscillatory frequencies with the arteriov-
enous extracorporeal lung assist device (ECLA) opened and closed. After recruitment and switching ventilation to 
HFOV the PaCO2 was significantly lower compared with lung injury (TARDS) (§p < 0.05). The PaCO2 were significantly reduced 
from 6 to 15 Hz with the ECLA opened (* p < 0.05).BMC Anesthesiology 2008, 8:7 http://www.biomedcentral.com/1471-2253/8/7
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applied (Fig. 3, p < 0.05). At the end of the study, gas
exchange parameters were not significantly different from
TRM (Table 1).
Hemodynamics and Oxygen Delivery
After lung recruitment, CVP, MPAP, PCWP and VO2 were
significantly elevated vs. TARDS (Table 1 and 2, p < 0.05).
CVP, MPAP and PCWP remained elevated compared with
TARDS  throughout the study; significant differences
between HFOV and HFOV/av-ECLA could be found in the
PCWP at 9 Hz and 15 Hz (Table 2, p < 0.05). Heart rate
and mean arterial pressure did not change significantly
compared with TARDS at different oscillatory frequencies.
At 3 Hz and 9 Hz, the HR was significantly higher during
HFOV/av-ECLA (Table 2, p < 0.05). MAP was significantly
elevated during HFOV at 3 Hz and 6 Hz. SVR was signifi-
cantly decreased and CO and DO2  were significantly
increased during HFOV/av-ECLA compared with HFOV
from 3 Hz to 15 Hz (Table 1 and 2, p < 0.05). PVR was sig-
nificantly higher during HFOV compared with HFOV/av-
ECLA between 6 Hz and 15 Hz (Table 2, p < 0.05). VO2
did not differ between study groups (Table 1).
Arteriovenous extracorporeal lung assist device
Blood gas analysis directly behind the membrane lung
resulted in an oxygen partial pressure from 564 ± 36
mmHg to 628 ± 22 mmHg. After applying higher oscilla-
tory frequencies, normocapnia was achieved by increasing
the O2-sweep gas flow from 2.4 ± 2.3 l/min to 5.0 ± 4.1 l/
min. Av-ECLA-blood flow was constant with 1.4 ± 0.2 l/
Mixed venous oxygen saturation (SvO2) during different oscillatory frequencies with the arteriovenous extracorporeal lung  assist device (ECLA) opened and closed Figure 3
Mixed venous oxygen saturation (SvO2) during different oscillatory frequencies with the arteriovenous extra-
corporeal lung assist device (ECLA) opened and closed. After recruitment and switching ventilation to HFOV the SvO2 
was significantly improved compared with lung injury (TARDS) (§p < 0.05). The SvO2 were significantly increased from 6 to15 Hz 
with the ECLA device opened (* p < 0.05).BMC Anesthesiology 2008, 8:7 http://www.biomedcentral.com/1471-2253/8/7
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min throughout the study, resulting in an av-ECLA-blood
flow/CO-ratio of 21 ± 6% to 27 ± 6%.
Discussion
The major findings of this study are twofold: (1) With
oscillatory frequencies from 9–15 Hz normocapnia could
only be maintained if HFOV was combined with av-ECLA.
(2) After lung recruitment and setting the mPaw 3 cmH2O
above Plow, a sustained improvement in oxygenation was
detectable even when oscillatory frequencies up to 15 Hz
were used.
Conventional mechanical ventilation during severe ARDS
can aggravate the progress of lung damage, especially
when high tidal volumes are applied and repeated tidal
collapse and reopening of damaged lung units occur. Lim-
itation of the VT to 6 ml/kg of the predicted body weight,
while keeping the lungs open with sufficient positive end-
expiratory pressure (PEEP) can significantly reduce mor-
tality in ARDS [3,4]. Further minimization of the VT com-
bined with the application of high mean airway pressures
may be achieved using HFOV [6]. Thereby, inspiratory
overdistension and expiratory de-recruitment can be
avoided [21]. Recently, it has been shown in a large-ani-
mal model of ARDS, that HFOV reduces histological signs
of lung inflammation and messenger RNA expression of
interleukin-1-beta in lung tissue compared to conven-
tional lung-protective ventilation [22]. In most clinical
studies using HFOV in adults, oscillatory frequencies
between 3–6 Hz and pressure amplitudes between 60–90
cmH2O have been used [10,11]. If hypercapnia was evi-
dent during HFOV then oscillatory frequencies were
decreased to 3 Hz and amplitudes were increased up to
90–100 cmH2O. However, oscillatory frequencies below
Arterial oxygen partial pressure (PaO2) during different oscillatory frequencies with the arteriovenous extracorporeal lung  assist device (ECLA) opened and closed Figure 4
Arterial oxygen partial pressure (PaO2) during different oscillatory frequencies with the arteriovenous extra-
corporeal lung assist device (ECLA) opened and closed. After lung recruitment and switching ventilation to HFOV the 
PaO2 was significantly higher compared with lung injury (TARDS) (§p < 0.05). PaO2 remained significantly improved with rising 
oscillatory frequencies compared with TARDS (§p < 0.05). The PaO2 was significantly increased at 15 Hz with the ECLA opened 
(* p < 0.05).BMC Anesthesiology 2008, 8:7 http://www.biomedcentral.com/1471-2253/8/7
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4 Hz combined with maximum pressure amplitudes
resulted in tidal volumes comparable to conventional
lung-protective ventilation, thereby antagonizing the
potential advantages of HFOV [12].
The idea of decoupling ventilation and oxygenation was
introduced by Gattinoni et al [23-25]: Extracorporeal
CO2-elimination was provided by a veno-venous per-
fusion route with 20–30% of the cardiac output, whereas
oxygenation was maintained by mechanical ventilation.
Several animal and human trials showed the feasibility of
reducing ventilator requirements during pump-driven
extracorporeal CO2-removal [23,24,26,27]. However,
despite technical advances of these systems, several side-
effects and complications impede its benefits, e.g., pump-
induced traumatisation of blood cells, plasma leakage of
oxygenator membranes and activation of the coagulation
and inflammatory system.
Pumpless extracorporeal lung assist became feasible with
the introduction of low-resistance membrane lungs that
could be interposed into a simple arteriovenous shunt
between the femoral artery and vein [28]. With the
patient's heart as the driving force, the transmembranous
blood flow is up to 25–30% of the CO, thereby allowing
comparable CO2-elimination and reductions in ventila-
tory support achieved during pumpdriven extracorporeal
CO2-removal [19]. In an adult sheep model of respiratory
failure, av-ECLA allowed significant reductions in VTs
(from 15 ± 1.6 to 3 ± 1.5 ml/kg), peak inspiratory pres-
Table 1: Gas exchange, respiratory and arteriovenous extracorporeal lung assist parameters, before and after lung injury, post 
recruitment and during the time course
TBaseline TARDS TRM 3 Hz/ECLA 3 Hz 6 Hz/ECLA 6 Hz
RR 30+/-0 30+/-0 180+/-0§ 180+/-0§ 180+/-0§ 360+/-0§ 360+/-0§
mPaw 9.3+/-0.4§ 13.2+/-1.4 22.6+/-1.1§ 22.6+/-1.1§ 22.6+/-1.1§ 22.6+/-1.1§ 22.6+/-1.1§
FiO2 1.0+/-0 1.0+/-0 1.0+/-0 1.0+/-0 1.0+/-0 1.0+/-0 1.0+/-0
pHa 7.45+/-0.09 7.41+/-0.06 7.55+/-0.04§ 7.6+/-0.04§ 7.58+/-0.07§ 7.48+/-0.07 7.4+/-0.08*
PaO2 585+/-24§ 60+/-12 532+/-116§ 563+/-69§ 551+/-75§ 549+/-68§ 556+/-60§
PaCO2 37.7+/-4.2 42.7+/-5.3 27.7+/-3.5§ 27.1+/-6§ 26.3+/-5.3§ 34+/-4.6 44.6+/-12.5*
SvO2 86.1+/-4.1§ 67.9+/-6.1 85.5+/-2.7§ 89.1+/-3.2§ 82.4+/-6.3§ 86.8+/-3.7§ 76.8+/-6.7§*
DO2 906+/-295 739+/-251 919+/-223 920+/-198 706+/-189* 804+/-192 593+/-211*
VO2 197+/-35 169+/-30 214+/-34§ 192+/-31 184+/-31 182+/-39 182+/-38
Qs/Qt 0.07+/-0.02§ 0.54+/-0.09 0.12+/-0.09§ 0.11+/-0.07§ 0.1+/-0.06§ 0.11+/-0.06§ 0.07+/-0.04§*
Plow 5.8+/-0.5§ 19.6+/-1.1
PECLAO2 564+/-36 574+/-45
SGF 0+/-0 2.4+/-2.3
EBF 1.4+/-0.2 1.4+/-0.2
EBF/CO 21+/-6 25+/-6
9 Hz/ECLA 9 Hz 12 Hz/ECLA 12 Hz 15 Hz/ECLA 15 Hz End
RR 540+/-0§ 540+/-0§ 720+/-0§ 720+/-0§ 900+/-0§ 900+/-0§ 180+/-0§
mPaw 22.6+/-1.1§ 22.6+/-1.1§ 22.6+/-1.1§ 22.6+/-1.1§ 22.6+/-1.1§ 22.6+/-1.1§ 22.6+/-1.1§
FiO2 1.0+/-0 1.0+/-0 1.0+/-0 1.0+/-0 1.0+/-0 1.0+/-0 1.0+/-0
pHa 7.46+/-0.05 7.34+/-0.08* 7.45+/-0.05 7.29+/-0.08* 7.43+/-0.06 7.26+/-0.07* 7.54+/-0.05§
PaO2 554+/-74§ 553+/-56§ 557+/-71§ 542+/-59§ 550+/-53§ 508+/-70§S* 579+/-25§
PaCO2 37.5+/-4 53.2+/-13.3§* 39+/-4.2 61.1+/-13.7§* 39.9+/-5.5 66.8+/-12.7§* 29.5+/-3.6§
SvO2 86.5+/-3.1§ 74.2+/-5.5§* 86.1+/-3.2§ 75.5+/-4§* 85.3+/-4§ 75.7+/-7§* 80.7+/-4.5§
DO2 764+/-152 538+/-118* 767+/-110 558+/-135* 819+/-194 590+/-169* 616+/-76
VO2 177+/-38 181+/-32 180+/-34 181+/-36 194+/-33 182+/-29 178+/-38
Qs/Qt 0.1+/-0.07§ 0.06+/-0.03§* 0.1+/-0.07§ 0.06+/-0.04§* 0.1+/-0.05§ 0.08+/-0.04§ 0.08+/-0.03§
Plow 20.7+/-3.5
PECLAO2 608+/-36 628+/-22 620+/-28
SGF 3.9+/-4.1 5+/-4 5+/-4.1
EBF 1.5+/-0.2 1.4+/-0.2 1.4+/-0.3
EBF/CO 27+/-6 26+/-2 24+/-4
Data expressed as means ± standard deviation; ECLA, arteriovenous extracorporeal lung assist; ARDS, acute respiratory distress syndrome; PRM, 
post recruitment; RR, respiratory rate per minute; mPaw, mean pulmonary airway pressure in cmH2O; FiO2, fraction of inspired oxygen; PaO2, 
arterial oxygen partial pressure in mmHg; PaCO2, arterial carbon dioxide partial pressure in mmHg; SvO2, mixed venous oxygen saturation; DO2, 
oxygen; delivery in l/min/m2; VO2, oxygen consumption in l/min/m2;Qs/Qt, pulmonary shunt fraction; Plow, lower inflection point in cmH2O;PECLAO2, 
partial oxygen pressure behind lung assist in mmHg; SGF, Sweep Gas Flow in l/min; EBF, ECLA Blood Flow in l/min; CO, cardiac output; * p < 0.05 
ECLA vs. No ECLA; §p < 0.05 vs. TARDS.BMC Anesthesiology 2008, 8:7 http://www.biomedcentral.com/1471-2253/8/7
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sures (40 ± 2.1 to 20 ± 7.5 cmH2O) and minute ventila-
tion (10 ± 1.4 to 0.5 ± 0 L/min) [19].
The goal of this large-animal study of ARDS was to evalu-
ate the effects of HFOV during different oscillatory fre-
quencies on CO2-elimination with and without the
application of av-ECLA. Our results clearly demonstrate
that normocapnia was not achieved and respiratory acido-
sis developed if higher oscillatory frequencies (> 9 Hz)
were used without av-ECLA. Although 'permissive hyper-
capnia' might be one element of a lung-protective ventila-
tion strategy because of its potential beneficial effects,
such as suppression of lung inflammation, the safe level
of hypercapnia and the respiratory acidosis remains
unknown [29]. In addition, there are clinical situations
where hypercapnia is contraindicated, e.g. in patients with
decreased cerebral compliance [30].
It has now been accepted, that VT-reduction is the key fac-
tor to improving outcome and to protecting the lungs
from further damage, whereas the optimal VT remains
unclear [4,31]. In our study, the implementation of av-
ECLA allowed the use of maximal oscillatory frequencies
(up to 15 Hz), similar to those applied during neonatal
HFOV, without the risk of hypercapnia or respiratory aci-
dosis. Although not measured in this study, with the set-
tings chosen, the resulting VTs can safely be assumed to be
below 1 ml/kg of the predicted body weight [16,32]. Nev-
ertheless, mere VT-reduction during conventional ventila-
tion leads to low peak pressure ventilation favouring
further lung de-recruitment [33]. Very recently, Dembin-
ski and co-workers compared the use of av-ECLA and VT-
reduction to 3 ml/kg with a conventional low-tidal vol-
ume (6 ml/kg) ventilation strategy in a large-animal
model of ARDS [34]. After 24 hours, the VT-reduction in
the av-ECLA group resulted in a significant impairment of
oxygenation and an increase of the pulmonary shunt frac-
tion compared with the CMV group. However, the PEEP
levels used in this study were very low and insufficient in
preventing lung de-recruitment. In ARDS patients venti-
lated with low tidal volumes, de-recruitment is usually
reversed by a recruitment manoeuvre or prevented by an
adequate PEEP level [33]. Adjusting the mPaw level for
optimal lung recruitment remains difficult during HFOV.
Usually mPaw during HFOV is set 3 to 5 cmH2O higher
than the mPaw used during CMV [21]. In an animal
model of respiratory distress, it was shown that setting the
mPaw 6 cmH2O above the lower inflection point of the
pressure-volume curve yielded the best oxygenation [21].
Using a similar recruitment strategy, we found sustained
improvements of oxygenation, even with maximum oscil-
latory frequencies. Since VT can be minimized when
HFOV is combined with av-ECLA, an optimal recruitment
of lung volume appears to be essential in this setting.
The study design implies the following limitations: First,
we used an ARDS model based on surfactant-depletion. In
adults, not surfactant deficiency, but alveolar flooding is
the predominant mechanism in ARDS development with
surfactant-depleted lungs responding better to lung
Table 2: Haemodynamic variables before and after lung injury, post recruitment and during the time course
TBaseline TARDS TRM 3 Hz/ECLA 3 Hz 6 Hz/ECLA 6 Hz
HR/min 72+/-18 75+/-20 78+/-24 84+/-19 75+/-18* 75+/-19 71+/-17
MAP 66+/-3§ 81+/-8 79+/-8 74+/-9 83+/-13* 78+/-9 86+/-14*
CVP 4.3+/-3.2 4.8+/-2 11.5+/-1.9§ 10.3+/-1.5§ 10.4+/-1.3§ 9.9+/-1.6§ 10.8+/-1.8§
MPAP 13+/-3,3 15.6+/-2.1 22.3+/-2.3§ 23.5+/-3.5§ 22.1+/-3.4§ 24.1+/-3§ 25+/-3.9§
PCWP 6.1+/-2 7.3+/-2 14.6+/-3.2§ 13.1+/-1.6§ 12.3+/-1.3§ 13.1+/-2§ 12.8+/-2.1§
CO 5.6+/-1.5 6.8+/-2 6.7+/-1.4# 6.8+/-2 5.3+/-1.8* 6+/-1.9 4.4+/-2§*
SVR 926+/-264 950+/-232 845+/-228# 801+/-253 1220+/-449* 968+/-260 1506+/-511§*
PVR 98+/-20 106+/-29 94+/-46# 134+/-61 168+/-75 159+/-66 269+/-168§*
9 Hz/ECLA 9 Hz 12 Hz/ECLA 12 Hz 15 Hz/ECLA 15 Hz End
HR/min 69+/-17 60+/-15* 71+/-16 62+/-14* 69+/-19 63+/-21 74+/-13
MAP 80+/-13 84+/-14 77+/-11 80+/-13 77+/-10 75+/-15 87+/-10
CVP 11+/-1.7§ 11+/-2.3§ 10.9+/-1.6§ 10.6+/-1.2§ 11.3+/-1.6§ 10.1+/-1.8§ 10.4+/-1.4§
MPAP 25.1+/-1.8§ 25.3+/-3§ 23.8+/-1.9§ 25.1+/-3.5§ 23.3+/-3§ 25+/-3,9§ 23.5+/-3.6§
PCWP 13.9+/-1.5§ 12.3+/-1.3§* 13.3+/-1.3§ 12.8+/-1.8§ 14.6+/-2.1§ 13.3+/-1.3§* 12.6+/-0.9§
CO 5.7+/-1.5 4+/-1§* 5.6+/-0.7 4.1+/-0.9§* 6+/-1.1 4.3+/-1.1§* 4.5+/-0.6§
SVR 1008+/-226 1542+/-405§* 949+/-140 1385+/-285§* 900+/-142 1224+/-262* 1404+/-330§
PVR 171+/-54 282+/-100§* 154+/-44 242+/-58§* 119+/-38 218+/-63§* 202+/-88§
Data expressed as means ± standard deviation; ECLA, arteriovenous extracorporeal lung assist; ARDS, acute respiratory distress syndrome; PRM, 
post recruitment; HR, heart rate; MAP, mean arterial blood pressure in mmHg; MPAP, mean pulmonary artery pressure in mmHg; PCWP, pulmonary 
artery occlusion pressure in mmHg; CO, cardiac output in l/min; SVR, systemic vascular resi stance in dyne·s/cm5; PVR, pulmonary vascular resi 
stance in dyne·s/cm5; * p < 0.05 ECLA vs. No ECLA; §p < 0.05 vs. TARDS; # p < 0.05 TRM vs. End.BMC Anesthesiology 2008, 8:7 http://www.biomedcentral.com/1471-2253/8/7
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recruitment [35]. Second, the Sensormedics 3100 B oscil-
lator is a pressure cycling machine that can neither control
nor directly measure VTs. Hence, in this study no direct
statement regarding the applied VTs can be made. How-
ever, in a recent observational study VT was measured
directly during HFOV in ARDS patients: It was shown, that
the tidal volumes during HFOV with frequencies between
5 and 12 Hz are between 0.8 and 3.3 ml/kg of the pre-
dicted body weight [12]. Third, the study protocol did not
allow alterations of the pressure amplitude and I:E-ratio
in order to improve CO2-elimination. Both parameter set-
tings refer to previous experimental large-animal studies
of HFOV and clinical practice [11,22,36]. However, if
maximal oscillatory frequencies without av-ECLA were
used, only moderate hypercapnia and respiratory acidosis
developed. Therefore, one might argue, that without av-
ECLA CO2-elimination could have been improved by
adjusting the pressure amplitude and I:E-ratio to 90–100
cmH2O and 1:2, respectively. On the other hand, with
near total CO2-removal due to extracorporeal lung assist,
the applied pressures and accordingly the applied VT
could have been further reduced, thereby minimizing VT
and alveolar shear stress. Finally, av-ECLA allows for
decoupling of ventilation and oxygenation. Therefore, the
application of more lung-protective ventilator settings is
not only possible, but should also be examined. However,
it was not the purpose of this study to examine the effect
of higher frequency HFOV on lung damage.
Despite the potential benefits with regard to lung protec-
tive ventilation strategies, different complications are
described during av-ECLA. These included infections,
ischemia of the lower limb after cannulation, bleeding
and cannula thrombosis [16]. In addition, the device
should not be used in patients with cardiogenic shock,
heparin-induced thrombocytopenia and severe peripheral
arterial occlusive disease.
Conclusion
In conclusion, we demonstrate in a large-animal model of
ARDS, that the combination of HFOV and av-ECLA guar-
antees normocapnia even with maximal oscillatory fre-
quencies of 9 to 15 Hz. In this context, av-ECLA can be
interpreted as a tool to unmask the entire lung protective
potential of HFOV. Minimization of the applied VT does
not only limit tidal overdistension and volutrauma, but
also facilitates lung recruitment and prevents the lungs
from atelactrauma since the application of higher mean
airway pressures is possible. Thereby, oxygenation can be
maintained. Histologic and immunologic data are needed
in order to prove the lung protective effects of the pro-
posed therapeutic concept.
In a further trial, it should be evaluated whether the com-
bination of HFOV with maximal oscillatory frequencies
and the av-ECLA result in further lung-protection when
compared to conventional lung-protective ventilation.
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